- Agency: GoingClear
- Client: ai3.Bio
- Category: Website Design — Technology
- Location: Boston, Massachusetts, United States
- Project Brief: Create a technology website for ai3.Bio that communicates its innovative approach to autoimmune disease research through clear scientific storytelling, modern visuals, and a scalable WordPress design system.
Technology companies in the life sciences face a tight launch window when a public debut and a funding announcement land on the same day. GoingClear designed the website for ai3.Bio, a biotech company that uses AI and immunology to target disease-causing T cells, in time for its public launch and $48 million Series A news.
The homepage opens on a two-line headline: Precision Research. AI Accelerated. Lime green periods close each line against a deep navy background, and a hot pink Discover the Science button sits below the subhead.
Lime circles and dot grids carry the brand through every section. Large chartreuse discs sit behind cropped lab photography, and a small tri-color dot label tops each heading set in a rounded geometric sans-serif.
The STARx Platform section explains two therapies side by side. Navy cards for the LNP/mRNA Platform and Antibody Platform each carry a short summary and a pink link button under the line “Two Platforms. One Target: CD161+ T Cells.”
A full-width statement block puts the patient need in plain numbers. White text notes that more than 15 million Americans live with autoimmune disease, and a closing line in lime states that ai3.Bio was founded to change that.
The newsroom and contact pages extend the same navy, lime, and pink system. Latest News & Insights runs as a horizontal carousel of photo-led article cards, and the contact page sets a white form card with a full-width pink Submit button against the navy background.
The layout scales from desktop to phone on WordPress CMS. On mobile, the navigation collapses into a pink menu button next to Contact Us, and the CMS leaves room for the pillar pages and added motion planned for the next phase.
